Unifying the Aminohexopyranose- and Peptidyl-Nucleoside Antibiotics: Implications for Antibiotic Design

Angew Chem Int Ed Engl. 2020 Jul 6;59(28):11330-11333. doi: 10.1002/anie.202003094. Epub 2020 May 11.

Abstract

In search of new anti-tuberculars compatible with anti-retroviral therapy we re-identified amicetin as a lead compound. Amicetin's binding to the 70S ribosomal subunit of Thermus thermophilus (Tth) has been unambiguously determined by crystallography and reveals it to occupy the peptidyl transferase center P-site of the ribosome. The amicetin binding site overlaps significantly with that of the well-known protein synthesis inhibitor balsticidin S. Amicetin, however, is the first compound structurally characterized to bind to the P-site with demonstrated selectivity for the inhibition of prokaryotic translation. The natural product-ribosome structure enabled the synthesis of simplified analogues that retained both potency and selectivity for the inhibition of prokaryotic translation.

Keywords: amicetin; antibiotic; blasticdin S; ribosome; translation inhibitor.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antitubercular Agents / chemistry*
  • Antitubercular Agents / pharmacology
  • Chlorocebus aethiops
  • Crystallography, X-Ray
  • Drug Design*
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis / drug effects
  • Peptides / chemistry*
  • Pyrans / chemistry*
  • Pyrimidine Nucleosides / chemistry
  • THP-1 Cells
  • Thermus thermophilus / chemistry
  • Vero Cells

Substances

  • Antitubercular Agents
  • Peptides
  • Pyrans
  • Pyrimidine Nucleosides
  • amicetin